4.7 Article

Novel THAP1 sequence variants in primary dystonia

Journal

NEUROLOGY
Volume 74, Issue 3, Pages 229-238

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181ca00ca

Keywords

-

Funding

  1. Medtronic Inc
  2. NIH [1R01 NS41509, R01 NS050425, R01 NS058714, P30 NS057105, 5R01 NS037167-10, U10 NS44455, R01HG02449, R01 ES01374301A2, P42 ES04696, K24 NS060825, R21 ES017504, K23 NS43351, RO1 NS050425, 1R01NS41509, RO1 NS058714, P01AG017216-1, R01AG015866-1, P50NS 40256, CIHR P 121849]
  3. NIH/NCRR [RR024992, R01ES013743, R01 NS039821, R01NS058797, RO1 HD056015, U54 NS065701]
  4. Huntington Disease Society of American Center of Excellence
  5. Michael J. Fox Foundation
  6. HiQ Foundation
  7. McDonnell Center for Higher Brain Function
  8. Greater St. Louis Chapter of the American Parkinson Disease Association
  9. Bander Foundation for Medical Ethics and Advanced PD Research Center at Washington University
  10. BJH Foundation
  11. BJHF/ICTS
  12. Mayo Clinic Florida
  13. PARF [C06-01]
  14. Novartis
  15. Eisai Inc.
  16. Advanced Neuromodulations Systems
  17. NIH/NINDS [P50NS 40256, 1R01NS058988, U10 NS44482, R01 NS037167, 1R03NS053840, R01NS048458, 5U01 NS052592]
  18. Michael J. Fox
  19. National Parkinson Foundation
  20. Allergan
  21. Boehringer Ingelheim
  22. Valeant
  23. Teva Neurosciences
  24. Schwarz
  25. Solvay
  26. Neurogen
  27. Ipsen
  28. Teva
  29. UCB Pharma Merz
  30. Schering Plough
  31. Acadia
  32. Merz Pharma
  33. Revance Therapeutics
  34. Dystonia Medical Research Foundation
  35. Bachmann-Strauss Dystonia & Parkinson Foundation
  36. Xenoport
  37. HP Therapeutics Foundation

Ask authors/readers for more resources

Background: THAP1 encodes a transcription factor (THAP1) that harbors an atypical zinc finger domain and regulates cell proliferation. An exon 2 insertion/deletion frameshift mutation in THAP1 is responsible for DYT6 dystonia in Amish-Mennonites. Subsequent screening efforts in familial, mainly early-onset, primary dystonia identified additional THAP1 sequence variants in non-Amish subjects. Objective: To examine a large cohort of subjects with mainly adult-onset primary dystonia for sequence variants in THAP1. Methods: With high-resolution melting, all 3 THAP1 exons were screened for sequence variants in 1,114 subjects with mainly adult-onset primary dystonia, 96 with unclassified dystonia, and 600 controls (400 neurologically normal and 200 with Parkinson disease). In addition, all 3 THAP1 exons were sequenced in 200 subjects with dystonia and 200 neurologically normal controls. Results: Nine unique melting curves were found in 19 subjects from 16 families with primary dystonia and 1 control. Age at dystonia onset ranged from 8 to 69 years (mean 48 years). Sequencing identified 6 novel missense mutations in conserved regions of THAP1 (G9C [cervical, masticatory, arm], D17G [cervical], F132S [laryngeal], I149T [cervical and generalized], A166T [laryngeal], and Q187K [cervical]). One subject with blepharospasm and another with laryngeal dystonia harbored a c.-42C>T variant. A c.57C>T silent variant was found in 1 subject with segmental craniocervical dystonia. An intron 1 variant (c.71 + 9C>A) was present in 7 subjects with dystonia (7/1,210) but only 1 control (1/600). Conclusions: A heterogeneous collection of THAP1 sequence variants is associated with varied anatomical distributions and onset ages of both familial and sporadic primary dystonia. Neurology (R) 2010; 74: 229-238

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available